NCT03477500View on ClinicalTrials.gov

Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 21, 2018

Primary Completion Date

November 21, 2026

Study Completion Date

March 21, 2028

Conditions
Multiple Sclerosis
Interventions
DRUG

Cyclophosphamide and ATG

Hematopoetic stem cell transplantation

DRUG

Alemtuzumab

Alemtuzumab (Lemtrada)

DRUG

Cladribine Pill

Cladribine (Mavenclad)

DRUG

Ocrelizumab

Ocrelizumab (Ocrevus)

Trial Locations (8)

Unknown

Rigshospitalet, Copenhagen

VUmc, Amsterdam

Haukeland University Hospital, Bergen

Akershus University Hospital, Oslo

University Hospital of North Norway, Tromsø

St. Olav's University Hospital, Trondheim

Sahlgrenska University Hospital, Gothenburg

Akademiska sjukhuset, Uppsala

All Listed Sponsors
lead

Haukeland University Hospital

OTHER